News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
269,003 Results
Type
Article (14402)
Company Profile (282)
Press Release (254319)
Multimedia
Podcasts (48)
Webinars (7)
Section
Business (79926)
Career Advice (170)
Deals (13282)
Drug Delivery (35)
Drug Development (50673)
Employer Resources (34)
FDA (5755)
Job Trends (5166)
News (145125)
Policy (10143)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (6)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (3)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (930)
Accelerated approval (2)
Adcomms (12)
Allergies (51)
Alliances (21742)
ALS (63)
Alzheimer's disease (845)
Antibody-drug conjugate (ADC) (89)
Approvals (5773)
Artificial intelligence (120)
Autoimmune disease (17)
Automation (5)
Bankruptcy (105)
Best Places to Work (4590)
BIOSECURE Act (6)
Biosimilars (43)
Biotechnology (232)
Bladder cancer (47)
Brain cancer (20)
Breast cancer (146)
Cancer (1363)
Cardiovascular disease (116)
Career advice (147)
Career pathing (3)
CAR-T (110)
Cell therapy (313)
Cervical cancer (8)
Clinical research (41107)
Collaboration (518)
Compensation (252)
Complete response letters (13)
COVID-19 (1094)
CRISPR (39)
C-suite (154)
Cystic fibrosis (76)
Data (1423)
Denatured (11)
Depression (29)
Diabetes (130)
Diagnostics (1305)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (82)
Drug pricing (29)
Drug shortages (3)
Duchenne muscular dystrophy (88)
Earnings (29881)
Editorial (21)
Employer branding (4)
Employer resources (32)
Events (48582)
Executive appointments (442)
FDA (6418)
Featured Employer (31)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (489)
Gene editing (93)
Generative AI (10)
Gene therapy (239)
GLP-1 (365)
Government (1111)
Grass and pollen (2)
Guidances (19)
Healthcare (6693)
Huntington's disease (22)
IgA nephropathy (22)
Immunology and inflammation (88)
Indications (18)
Infectious disease (1160)
Inflammatory bowel disease (111)
Inflation Reduction Act (9)
Influenza (19)
Intellectual property (63)
Interviews (19)
IPO (7309)
IRA (11)
Job creations (865)
Job search strategy (139)
Kidney cancer (6)
Labor market (5)
Layoffs (206)
Leadership (5)
Legal (1407)
Liver cancer (31)
Lung cancer (194)
Lymphoma (89)
Machine learning (2)
Management (9)
Manufacturing (126)
MASH (50)
Medical device (2647)
Medtech (2648)
Mergers & acquisitions (6291)
Metabolic disorders (377)
Multiple sclerosis (51)
NASH (13)
Neurodegenerative disease (63)
Neuropsychiatric disorders (23)
Neuroscience (1237)
NextGen: Class of 2025 (2057)
Non-profit (896)
Northern California (1626)
Now hiring (22)
Obesity (192)
Opinion (108)
Ovarian cancer (61)
Pain (41)
Pancreatic cancer (53)
Parkinson's disease (120)
Partnered (8)
Patents (124)
Patient recruitment (69)
Peanut (35)
People (25708)
Pharmaceutical (48)
Pharmacy benefit managers (5)
Phase I (14510)
Phase II (19133)
Phase III (12107)
Pipeline (778)
Policy (44)
Postmarket research (852)
Preclinical (6096)
Press Release (30)
Prostate cancer (57)
Psychedelics (35)
Radiopharmaceuticals (212)
Rare diseases (286)
Real estate (1439)
Recruiting (14)
Regulatory (8667)
Reports (15)
Research institute (945)
Resumes & cover letters (18)
Rett syndrome (4)
RNA editing (4)
RSV (11)
Schizophrenia (57)
Series A (95)
Series B (60)
Service/supplier (1)
Sickle cell disease (40)
Southern California (1432)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (11)
Startups (1977)
State (1)
Stomach cancer (4)
Supply chain (20)
Tariffs (6)
The Weekly (36)
United States (12697)
Vaccines (212)
Venture capitalists (29)
Weight loss (109)
Women's health (15)
Worklife (2)
Date
Today (60)
Last 7 days (276)
Last 30 days (1481)
Last 365 days (19674)
2025 (5473)
2024 (20607)
2023 (22490)
2022 (26936)
2021 (28030)
2020 (23713)
2019 (16376)
2018 (11891)
2017 (13837)
2016 (11921)
2015 (14412)
2014 (10455)
2013 (7522)
2012 (7565)
2011 (7644)
2010 (7456)
Location
Africa (149)
Alabama (41)
Alaska (2)
Arizona (53)
Arkansas (6)
Asia (17321)
Australia (2961)
California (3690)
Canada (1096)
China (333)
Colorado (149)
Connecticut (147)
Delaware (93)
Europe (37268)
Florida (445)
Georgia (115)
Idaho (16)
Illinois (220)
India (10)
Indiana (90)
Iowa (1)
Japan (73)
Kansas (61)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (463)
Massachusetts (2918)
Michigan (71)
Minnesota (143)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (929)
New Mexico (12)
New York (997)
North Carolina (537)
North Dakota (4)
Northern California (1626)
Ohio (109)
Oklahoma (9)
Oregon (21)
Pennsylvania (702)
Puerto Rico (5)
Rhode Island (16)
South America (217)
South Carolina (4)
Southern California (1432)
Tennessee (25)
Texas (423)
Utah (50)
Virginia (74)
Washington D.C. (30)
Washington State (337)
Wisconsin (14)
269,003 Results for "storm therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
FDA
FDA After the Storm: Drug Review Delays and Increased Executive Oversight Expected
After the gutting of the Department of Health and Human Services, fears mount about the future direction of the FDA—with regulatory experts predicting delays in drug approvals and greater influence of political appointees.
April 14, 2025
·
6 min read
·
Heather McKenzie
Editorial
FDA Weathers Bait-and-Switch Storm as Staff and Sites Come and Go
Marty Makary, likely FDA commissioner under President Trump, appeared before Congress this week as the agency he’s set to lead continues to be rocked by sweeping changes and about-faces.
March 7, 2025
·
3 min read
·
Jef Akst
Biotech Beach
First Patient in STORM-PE RCT Enrolled Evaluating Penumbra’s Latest Computer Assisted Vacuum Thrombectomy - Lightning Flash™ - for Treatment of Acute Pulmonary Embolism
Penumbra, Inc. announced the first patient enrolled in STORM-PE, a first-of-its-kind prospective, multi-center, randomized controlled trial evaluating anticoagulation alone vs anticoagulation plus Lightning Flash™ for the treatment of pulmonary embolism (PE).
November 28, 2023
·
6 min read
Drug Development
Trefoil Therapeutics’ Lead Investigational Candidate TTHX1114 Improves Rate of Visual Recovery after Descemet Stripping Only (DSO) in Phase 2 STORM Data Presented at ASCRS Annual Meeting
Trefoil Therapeutics today announced that TTHX1114 was found to improve the rate of visual recovery and corneal deturgescence (state of relative dehydration maintained by the normal cornea that is necessary for transparency) after Descemet Stripping Only (DSO) in a dose-responsive manner in the Phase 2 STORM study.
May 8, 2023
·
5 min read
Layoffs
Spark Therapeutics Cuts 298 Employees as Part of Reorganization
Roche’s reorganization of Spark Therapeutics is coming more into focus, with nearly 300 employees being let go by the end of this year. Spark also trimmed its staff in 2024.
April 4, 2025
·
1 min read
·
Angela Gabriel
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Business
Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes
Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer.
October 14, 2021
·
8 min read
Press Releases
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
April 17, 2025
·
13 min read
Press Releases
Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics
April 15, 2025
·
7 min read
Policy
FDA Provides Update Regarding Storm Damage at Pfizer Facility in North Carolina
The U.S. Food and Drug Administration is working closely with Pfizer to assess the impact of the damage at Pfizer’s Rocky Mount, North Carolina, facility.
July 21, 2023
·
3 min read
1 of 26,901
Next
